Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$2.16 USD
+0.05 (2.37%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $2.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRBU 2.16 +0.05(2.37%)
Will CRBU be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRBU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBU
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
CRBU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?
Other News for CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Caribou Biosciences: A Strong Buy on Solid Financials and Promising Trials
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
Caribou Biosciences Ltp appoims Albertso as CMO